Prospective validation of the Chinese University Prognostic Index and comparison with other staging systems for hepatocellular carcinoma in an Asian population

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 2, 2011, Pages 340-347

  Chan, Stephen L ^a   Mo, Frankie K F ^a   Johnson, Philip J ^d   Liem, Giok S ^a   Chan, Tung C ^a   Poon, Ming C ^a   Ma, Brigette B Y ^a   Leung, Thomas W T ^b   Lai, Paul B S ^c   Chan, Anthony T C ^a   Mok, Tony S K ^a   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Comparison; Hepatitis B infection; Hepatocellular carcinoma; Staging system

Indexed keywords

ALPHA FETOPROTEIN;

ADULT; ARTICLE; ASIA; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM;

EID: 78851469081     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06329.x     Document Type: Article

References (43)

1. Okuda K, Ohtsuki T, Obata H etal. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56: 918-28.
2. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998; 28: 751-5.
3. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin. Liver Dis. 1999; 19: 329-38.
4. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J. Hepatol. 1999; 31: 133-41.
5. Leung TW, Tang AM, Zee B etal. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002; 94: 1760-9.
6. Kudo M, Chung H, Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J. Gastroenterol. 2003; 38: 207-15.
7. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford) 2005; 7: 35-41.
8. Sobin LH, Wittekind C, authors, eds. TNM Classificaiton of Malignant Tumours, 5th edn. New York: John Wiley & Sons, 1997.
9. Vauthey JN, Lauwers GY, Esnaola NF etal. Simplified staging for hepatocellular carcinoma. J. Clin. Oncol. 2002; 20: 1527-36.
10. Orlandi F, Christensen E. A consensus conference on prognostic studies in hepatology. J. Hepatol. 1999; 30: 171-2.
11. Johnson P, Bruix J. Hepatocellular carcinoma and the art of prognostication. J. Hepatol. 2000; 33: 1006-8.
12. Abou-Alfa GK, Huitzil-Melendez FD, O'Reilly EM, Saltz LB. Current management of advanced hepatocellular carcinoma. Gastrointest. Cancer Res. 2008; 2: 64-70.
13. Camma C, Cabibbo G. Prognostic scores for hepatocellular carcinoma: none is the winner. Liver Int. 2009; 29: 478-80.
14. Abou-Alfa GK. Hepatocellular carcinoma: molecular biology and therapy. Semin. Oncol. 2006; 33: S79-83.
15. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003; 362: 2089-94.
16. Chen CH, Huang GT, Yang PM etal. Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis. Eur. J. Cancer 2006; 42: 2524-9.
17. Shiratori Y, Shiina S, Imamura M etal. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22: 1027-33.
18. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am. J. Gastroenterol. 2002; 97: 2886-95.
19. Nishida N, Nagasaka T, Nishimura T, Ikai I, Boland CR, Goel A. Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology 2008; 47: 908-18.
20. Ikeda K, Saitoh S, Koida I etal. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
21. Okuda H. Hepatocellular carcinoma development in cirrhosis. Best Pract. Res. Clin. Gastroenterol. 2007; 21: 161-73.
22. Gentilini P, Melani L, Riccardi D, Casini Raggi V, Romanelli RG. Hepatocellular carcinoma and viral cirrhosis. Hepatology 1994; 20: 764-5.
23. Okuda H, Obata H, Motoike Y, Hisamitsu T. Clinicopathological features of hepatocellular carcinoma-comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology 1984; 31: 64-8.
24. Shijo H, Okazaki M, Koganemaru F, Higashi M, Sakaguchi S, Okumura M. Influence of hepatitis B virus infection and age on mode of growth of hepatocellular carcinoma. Cancer 1991; 67: 2626-32.
25. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
26. Yu SC, Hui EP, Wong J etal. Transarterial ethanol ablation of hepatocellular carcinoma with lipiodol ethanol mixture: phase II study. J. Vasc. Interv. Radiol. 2008; 19: 95-103.
27. Levy I, Sherman M. Staging of hepatocellular carcinoma: assessment of the CLIP, Okuda, and Child-Pugh staging systems in a cohort of 257 patients in Toronto. Gut 2002; 50: 881-5.
28. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31: 840-5.
29. Ueno S, Tanabe G, Sako K etal. Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Cancer of the Liver Italian Program. Hepatology 2001; 34: 529-34.
30. Hosmer DW, Hosmer T, Le Cessie S, Lemeshow S. A comparison of goodness-of-fit tests for the logistic regression model. Stat. Med. 1997; 16: 965-80.
31. Feinstein AR. Clinical biostatistics. XVI. The process of prognostic stratification. 2. Clin. Pharmacol. Ther. 1972; 13: 609-24.
32. Choi SB, Lee JG, Kim KS etal. The prognosis and survival analysis according to seven staging systems of hepatocellular carcinoma following curative resection. Hepatogastroenterology 2008; 55: 2140-5.
33. Vauthey JN, Ribero D, Abdalla EK etal. Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: validation of a uniform staging after surgical treatment. J. American College Surgeons. 2007; 204: 1016-27; discussion 27-8.
34. Marrero JA, Fontana RJ, Barrat A etal. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-16.
35. Cillo U, Vitale A, Grigoletto F etal. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J. Hepatol. 2006; 44: 723-31.
36. Guglielmi A, Ruzzenente A, Pachera S etal. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am. J. Gastroenterol. 2008; 103: 597-604.
37. Grieco A, Pompili M, Caminiti G etal. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-18.
38. Chen CH, Hu FC, Huang GT etal. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method-analysis of 2010 Taiwanese patients. Eur. J. Cancer 2009; 45: 1630-9.
39. Seo YS, Kim YJ, Um SH etal. Evaluation of the prognostic powers of various tumor status grading scales in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2008; 23: 1267-75.
40. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
41. Huitzil-Melendez FD, Capanu M, O'Reilly EM etal. Ranking and improvement of staging systems (SS) in advanced hepatocellular carcinoma (AHCC). 2008 Gastrointestinal Cancers Symposium, American Society of Clinical Oncology. 2008; 210.
42. Collette S, Bonnetain F, Paoletti X etal. Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials. Ann Oncol. 2008; 19: 1117-26.
43. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359: 378-90.